Johnson & Johnson <JNJ.N> reported sharply better-than-expected quarterly revenue and earnings, fueled by strong sales of newer prescription drugs, including its Olysio treatment for hepatitis C.
Continue Reading Below
The diversified healthcare company on Tuesday said it earned $4.33 billion, or $1.51 per share, in the second quarter. That compared with $3.83 billion, or $1.33 per share, in the year-earlier period, when the company took charges for litigation and an acquisition.
Excluding special items, J&J earned $1.66 per share. Analysts, on average, were expecting $1.55 per share, according to Thomson Reuters I/B/E/S.
Company sales jumped 9.1 percent to $19.5 billion, well above Wall Street expectations of $18.99 billion.